FRANKFURT, March 20 (Reuters) - BioNTech

estimates that its 10 most advanced cancer treatment candidates

could generate combined peak sales of more than 10 billion euros

($10.9 billion), after reporting an ongoing decline in its

COVID-19 vaccine business.

"The peak sales estimate for that collection of assets is

actually well over 10 billion euros in our long term estimates,"

BioNTech's head of strategy, Ryan Richardson, said in analyst

call on Wednesday after the release of 2023 results.

He would not be drawn on a combined sales estimate for the

year 2030, when asked by an analyst.

Germany's BioNTech, whose COVID-19 vaccine in partnership

with Pfizer ( PFE ) was widely used during the pandemic, earlier

on Wednesday reported a plunge in 2023 revenue and earnings as

its focus shifts towards cancer drug development.

($1 = 0.9218 euros)

(Writing by Ludwig Burger, Editing by Rachel More)